Royalty Pharma (RPRX) EBIT Growth (3y) (2022 - 2026)
Royalty Pharma (RPRX) EBIT Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 16.96% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 38.78% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 13.47% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -12.10% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 69.02% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - | 5.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.54% |
| Dec 31, 2025 | 41.02% |
| Sep 30, 2025 | 30.50% |
| Jun 30, 2025 | -17.80% |
| Mar 31, 2025 | 34.46% |
| Dec 31, 2024 | 33.07% |
| Sep 30, 2024 | 34.36% |
| Jun 30, 2024 | -28.73% |
| Mar 31, 2024 | -32.42% |
| Dec 31, 2023 | 24.97% |
| Sep 30, 2023 | -33.31% |
| Jun 30, 2023 | -15.29% |
| Mar 31, 2023 | 9.84% |
| Dec 31, 2022 | -33.18% |
| Sep 30, 2022 | -28.80% |
| Jun 30, 2022 | 4.84% |